[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"content-doc-dcio05fb5f77":3},{"user":4,"document":8,"mainDocument":27,"columnUrl":29,"subscription":30,"footer":42,"text":80},{"isAuthenticated":5,"isAdmin":5,"displayName":6,"avatarUrl":6,"nid":6,"groupLevel":7},false,"",-10,{"id":9,"fullTitle":10,"subTitle":6,"url":11,"columnId":12,"columnName":13,"columnUrl":14,"summary":6,"contentHtml":15,"mainContentHtml":6,"posterUrl":16,"createDate":17,"displayDate":18,"displayDateSlash":19,"pageviews":20,"tags":21,"hidden":5,"isSubContent":5,"replyDocOrTargetId":6,"contentType":23,"videoId":6,"liveVideoUrl":6,"useContentVideo":5,"duration":24,"price":24,"priceText":25,"priceBadgeText":25,"priceBadgeClass":26,"freeForMinGroupLevel":24,"redirectUrl":6,"readyToStream":5},"dcio05fb5f77","美股Tempus AI（TEM）股价为什么大涨？","\u002Fdoc\u002Fdcio05fb5f77","col18178739ee","美股资讯","\u002Fcol\u002Fcol18178739ee","\u003Cp>\n\u003C\u002Fp>\u003Cp>\u003Cspan>Tempus AI\u003Cspan>（\u003C\u002Fspan>NASDAQ\u003Cspan>：\u003C\u002Fspan>TEM\u003Cspan>）股价今日大幅上涨，原因是投资者正在重新评估其核心癌症检测产品未来从\u003C\u002Fspan> Medicare\u003Cspan>（美国联邦医疗保险）报销中获得的潜在收入。此次上涨的直接催化剂来自管理层在摩根士丹利医疗健康大会上的讲话。管理层此次给出了更加明确、同时也更大的潜在收入区间。\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cspan>主要催化剂\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cspan>Tempus AI CEO Eric Lefkofsky \u003Cspan>表示，公司预计未来可能获得大约：\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cspan>2027\u003Cspan>年，基于组织样本的癌症检测产品，可获得约\u003C\u002Fspan>8000\u003Cspan>万至\u003C\u002Fspan>1\u003Cspan>亿美元的\u003C\u002Fspan> Medicare \u003Cspan>报销收入。\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cspan>\u003Cspan>液体活检（\u003C\u002Fspan>liquid biopsy\u003Cspan>）检测产品，可获得约\u003C\u002Fspan>2.5\u003Cspan>亿至\u003C\u002Fspan>3\u003Cspan>亿美元的\u003C\u002Fspan> Medicare \u003Cspan>报销收入。\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cspan>\u003Cspan>两项业务合计意味着，公司潜在的年度收入规模约为\u003C\u002Fspan>3.3\u003Cspan>亿至\u003C\u002Fspan>4\u003Cspan>亿美元。对于一家仍处于成长阶段的医疗\u003C\u002Fspan>AI\u003Cspan>诊断公司而言，这一收入规模具有相当重要的意义。\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cspan>\u003Cspan>随着\u003C\u002Fspan> Medicare \u003Cspan>支付标准和报销金额变得更加明确，投资者对于\u003C\u002Fspan> Tempus \u003Cspan>的癌症检测产品能够实现商业化规模扩张的信心也有所增强。这意味着这些检测产品可能不再只是具有技术潜力，而是有望真正形成可规模化的商业收入。\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cspan>\u003Cspan>为什么\u003C\u002Fspan> Medicare \u003Cspan>报销如此重要\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cspan>\u003Cspan>对于诊断公司而言，\u003C\u002Fspan>Medicare \u003Cspan>的报销政策是影响公司估值的重要因素之一，因为它能够直接决定：\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cspan>医疗机构是否具有足够强的经济动力去订购相关检测；\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cspan>公司每完成一次检测能够获得多少收入；\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cspan>检测业务的使用量能够以多快的速度增长；\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cspan>以及公司能否将临床领域的产品采用率转化为更加稳定、可预测的持续性收入。\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cspan>\u003Cspan>因此，市场此次的反应并不仅仅是因为\u003C\u002Fspan> Tempus \u003Cspan>发布了一款新产品，而是投资者对\u003C\u002Fspan> TEM\u003Cspan>未来每次检测所产生的经济价值（\u003C\u002Fspan>unit economics\u003Cspan>）以及未来收入可见度的判断出现了改善。\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cspan>MarketWatch \u003Cspan>同样将此次股价上涨归因于市场对于\u003C\u002Fspan> Tempus \u003Cspan>癌症检测产品未来可能获得的\u003C\u002Fspan> Medicare \u003Cspan>报销金额的预期。\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cspan>推动股价上涨的其他因素\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cspan>今天的上涨并非孤立事件，而是延续了此前几个交易日的强劲上涨趋势。\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cspan>\u003Cspan>据美股投资网报道，\u003C\u002Fspan>TEM \u003Cspan>周四盘中一度上涨约\u003C\u002Fspan>14%\u003Cspan>至\u003C\u002Fspan>15%\u003Cspan>，股价接近\u003C\u002Fspan>80\u003Cspan>美元，而此前一个交易日收盘价为\u003C\u002Fspan>69.97\u003Cspan>美元。\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cspan>\u003Cspan>本周以来，该股累计上涨约\u003C\u002Fspan>30%\u003Cspan>，过去五个交易日累计上涨约\u003C\u002Fspan>36%\u003Cspan>。随着\u003C\u002Fspan> Medicare \u003Cspan>报销前景变得更加明确，市场正在对\u003C\u002Fspan> Tempus \u003Cspan>的估值进行重新定价。\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cspan>\u003Cspan>与此同时，投资者也受到\u003C\u002Fspan> Tempus \u003Cspan>近期业务增长以及其医药公司和数据业务发展的鼓舞。其中，公司第二季度的数据授权业务订单表现受到关注，据报道涉及\u003C\u002Fspan> **AstraZeneca\u003Cspan>（阿斯利康）、\u003C\u002Fspan>GSK\u003Cspan>（葛兰素史克）以及\u003C\u002Fspan> Merck\u003Cspan>（默克）\u003C\u002Fspan>**\u003Cspan>等大型制药公司。\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cspan>Tempus \u003Cspan>此外还计划以约\u003C\u002Fspan>15\u003Cspan>亿美元收购\u003C\u002Fspan> Personalis\u003Cspan>。这进一步强化了市场对于\u003C\u002Fspan> Tempus \u003Cspan>正在打造更加完整的精准肿瘤学（\u003C\u002Fspan>precision oncology\u003Cspan>）和分子检测平台的预期。\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cspan>不过，收购交易本身也伴随着执行风险以及股权稀释风险。\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cspan>需要注意的重要因素\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cspan>如此大幅度的股价上涨，除了基本面因素之外，也可能受到市场动量以及空头回补等因素的影响。\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cspan>\u003Cspan>目前上述收入预测仍然属于前瞻性预期。\u003C\u002Fspan>Tempus \u003Cspan>最终能否实现这一收入区间，将取决于实际\u003C\u002Fspan> Medicare \u003Cspan>报销金额、检测产品的使用量、商业化进展、市场竞争情况，以及\u003C\u002Fspan> Personalis \u003Cspan>收购完成后的整合效果。\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cspan>美股投资网总结：\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cspan>TEM \u003Cspan>股价上涨的核心原因，是投资者认为\u003C\u002Fspan> Medicare \u003Cspan>报销未来可能为\u003C\u002Fspan> Tempus \u003Cspan>的癌症诊断业务带来每年数亿美元的新增收入，从而使公司的整体增长前景明显增强。\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cspan>━━━━━━━━━━━━━━━━━━━━━━\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cspan>【原创声明】\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cspan>\u003Cspan>本文由美股投资网（\u003C\u002Fspan>TradesMax.com\u003Cspan>）研究团队原创完成。\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cspan>原创机构：美股投资网\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cspan>\u003Cspan>英文品牌：\u003C\u002Fspan>TradesMax\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cspan>\u003Cspan>本文基于公开财报、\u003C\u002Fspan>SEC\u003Cspan>文件、市场数据、机构资金、期权交易及产业链信息进行独立分析\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cspan>如需引用本文，请注明：\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cspan>\u003Cspan>“美股投资网（\u003C\u002Fspan>TradesMax.com\u003Cspan>）原创研究”。\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cspan>━━━━━━━━━━━━━━━━━━━━━━\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003C\u002Fp>","https:\u002F\u002Fwww.tradesmax.com\u002Fimages\u002Fa_Stock\u002FT\u002FTEM\u002FTEM.jpg","2026-09-18T00:20:47","2026.09.18","2026\u002F09\u002F18",41175,[22],"TEM","Article",0,"免费","success",{"id":9,"fullTitle":10,"subTitle":6,"url":11,"columnId":12,"columnName":13,"columnUrl":14,"summary":6,"contentHtml":15,"mainContentHtml":6,"posterUrl":16,"createDate":17,"displayDate":18,"displayDateSlash":19,"pageviews":20,"tags":28,"hidden":5,"isSubContent":5,"replyDocOrTargetId":6,"contentType":23,"videoId":6,"liveVideoUrl":6,"useContentVideo":5,"duration":24,"price":24,"priceText":25,"priceBadgeText":25,"priceBadgeClass":26,"freeForMinGroupLevel":24,"redirectUrl":6,"readyToStream":5},[22],"\u002Fcol\u002Fstocknews",{"visible":5,"marketingHtml":31,"services":32,"recentDocuments":41},"\u003Cfigure class=\"image\">\u003Ca href=\"https:\u002F\u002Fstockwe.com\u002Fdoc\u002Fdcio537efad5\" rel=\"noopener noreferrer\">\u003Cimg src=\"\u002Fimg\u002Fstockwewebfiles\u002Fweb-202408-stk\u002F1586109431mceclip0.jpg\">\u003C\u002Fa>\u003C\u002Ffigure>\u003Cdiv class=\"text-center\">\u003Ch2 class=\"card-title mx-auto\">\u003Cbr>\u003Ca rel=\"noopener noreferrer\" href=\"https:\u002F\u002Fstockwe.com\u002Fdoc\u002Fdcio537efad5\">案例介绍：英伟达深度研究报告\u003C\u002Fa>\u003C\u002Fh2>\u003C\u002Fdiv>",[33,37],{"productId":34,"serviceName":35,"priceText":36},"prod_PPxdDdK87QaiLv","月付","$12.95美元",{"productId":38,"serviceName":39,"priceText":40},"prod_PPxeMs3bix1da5","年付","$149.00美元",[],{"links":43,"images":71,"summaryHtml":76,"aboutTitle":77,"aboutHtml":78,"copyrightHtml":79},[44,47,50,53,56,59,62,65,68],{"label":45,"url":46},"深度报告","\u002Fcol\u002FdepthReport",{"label":48,"url":49},"VIP会员","\u002Fvip",{"label":51,"url":52},"期权推荐","\u002FOption",{"label":54,"url":55},"低价暴涨股","\u002FPenny",{"label":57,"url":58},"AI智能体","\u002FAiAgent",{"label":60,"url":61},"常见问题","https:\u002F\u002Fstockwe.com\u002FFAQ",{"label":63,"url":64},"美股课程","\u002Fcol\u002Fvideos",{"label":66,"url":67},"免责声明","\u002Fdisclaimer",{"label":69,"url":70},"联系我们","\u002FContactUs",[72,73,74,75],"\u002Fimg\u002Fstockwebsiteblob\u002Fweb-202509-stk\u002FUploaderzic2tuwsol2_2025_09_11_18_21_07.gif","\u002Fimg\u002Fstockwebsiteblob\u002Fweb-202509-stk\u002FUploadercakzdvydksw_2025_09_03_09_00_56.png","\u002Fimg\u002Fstockwebsiteblob\u002Fweb-202509-stk\u002FUploadergtjyagwvoyk_2025_09_14_08_32_05.png","\u002Fimg\u002Fstockwebsiteblob\u002Fweb-202509-stk\u002FUploader3u0tt4jhlqh_2025_09_23_22_30_48.png","邮箱: buy@TradesMax.com 美国电话 626-378-3637","公司介绍","\u003Cp class=\"MsoNormal\">美股大数据 \u003Ca href=\"https:\u002F\u002Fstockwe.com\" rel=\"noopener\">StockWe.com\u003C\u002Fa> 是一个美国领先的金融和美股信息大数据提供商，紧盯华尔街金融市场和行情，2008年成立于美国硅谷，创始人是前纽约证券交易所资深分析师Ken，联合多位摩根斯坦利分析师，谷歌 Meta工程师利用AI和大数据，配合十多年美股实战经验和业内量化交易模型，每天处理海量股票数据：挖掘潜力大牛股，捕捉期权异动大单，实时主力资金流向、机构持仓变化、川普突发新闻，美股买卖信号第一时间发到您手机APP。\u003C\u002Fp>","专业美股投资者都在这里",{"loading":81,"search":82,"searchPlaceholder":82,"hotContent":83,"draft":84,"noData":85,"searchNoData":86,"courseContent":87,"more":88,"buyNow":89,"subscribeNow":90,"encoding":91,"paidContent":92},"Loading...","搜索","热门内容","草稿","目前没有任何内容公布","当前检索内容没有数据","课程内容","更多","立即购买后观看","- 立即订阅 -","视频编码中...","付费内容"]